Key Takeaways
- Strong quarter, guidance on track: Revenue grew 23% YoY to ₹786 crores (revenue from operations), and management is confident of meeting the upgraded "high teens" full-year revenue growth guidance.
- Biologics facility clears the final regulatory hurdle: The manufacturing site received cGMP certifications from the US FDA, EMA, and MHRA, positioning the company to fulfil its long-term Zoetis contract and pursue its broader biologics growth strategy.
- Margin compression from operating costs, not demand: EBITDA margin declined ~220 bps YoY to 29.4% as other expenses grew 33.2% and forex swung to a loss, partially offset by staff costs declining as a percentage of revenue.
- End-to-end injectables capability now online: The sterile fill-finish facility is GMP-compliant from Q4 FY23, adding drug product development and manufacturing for clinical supplies of injectables.
- What to watch next quarter: The pace of new business wins for the newly certified biologics facility and whether the inflationary pressure on other expenses persists into Q4.
Revenue Performance
- Broad-based growth: All divisions reported positive performances, with Research divisions (Discovery Services and Dedicated Centres) delivering solid growth and Development Services benefitting from repeat orders and new collaborations with emerging biopharma companies.
- Geographic demand intact: Good demand in the main client markets of the US and Europe, combined with strong execution and forward planning, drove the 23% YoY revenue increase.
- 9M momentum: Nine-month revenue from operations grew 19.1% YoY, with material costs declining as a percentage of revenue from 28.9% to 25.8%, partially offsetting a 36.8% YoY rise in other expenses.
Hunt: "We continue to see good demand in the main client markets of US and Europe which - combined with strong execution and forward planning - has helped us deliver solid revenue growth in the third quarter."
Biologics Manufacturing Milestone
- Triple-agency certification achieved: The biologics manufacturing facility successfully completed regulatory audits by the US FDA, EMA, and MHRA, receiving cGMP certifications that were the highlight of the quarter.
- Zoetis contract now unlocked: With certifications in place, the company is well positioned to fulfil its long-term contract with Zoetis and progress its biologics growth strategy.
- Sterile fill-finish adds the final piece: Construction of the sterile fill-finish facility was completed and it cleared a CDSCO inspection, making it compliant for GMP production from Q4 FY23 onwards, offering end-to-end solutions in drug product development and manufacturing for clinical supplies of small and large molecule injectables.
Hunt: "With Good Manufacturing Practice (cGMP) certifications from the regulatory agencies in place, the Company is well positioned to fulfil its long-term contract with Zoetis and progress its biologics growth strategy."
Profitability & Margins
- EBITDA margin declined on cost headwinds: EBITDA margin fell ~220 bps YoY to 29.4% because other expenses grew 33.2% YoY and foreign exchange swung from a gain of 19.9 crore to a loss of 15.6 crore, partially offset by staff costs declining as a percentage of revenue from 30.5% to 27.9%.
- PAT growth muted by below-the-line items: PAT before exceptional item grew only 5.5% YoY to ₹110 crores as EBITDA growth of 14.8% was largely absorbed by higher depreciation (+20.6%), higher finance costs (+46.2%), and higher tax (+24.0%).
- 9M margin trend similar: Nine-month EBITDA margin declined ~140 bps YoY to 28.2%, with forex swinging from a gain of 45.7 crore to a loss of 37.6 crore, partially offset by material costs declining as a percentage of revenue.
Leadership & Capability Build
- Development Services leadership: Joydeep Kant joined in November 2022 as SVP Development Services and Executive Committee member, bringing experience from Zoetis, Pfizer, Bristol-Myers Squibb, Johnson Matthey Pharmaceuticals, and Ranbaxy.
- CHRO appointment: Andrew Webster joined in December 2022 as Chief Human Resources Officer and Executive Committee member, with prior roles at Teneo, DFS, AstraZeneca PLC, and Marks and Spencer PLC.
Inflation & Cost Management
- Inflationary pressures acknowledged: Management stated they are facing inflationary pressures in line with the global trend but have been largely successful in navigating such issues to date.
- Staff cost leverage evident: Staff costs declined as a percentage of revenue from 30.5% to 27.9% YoY in Q3, providing a partial offset to the rise in other expenses.
Biswas: "In line with the global trend, we are also facing inflationary pressures, but we have been largely successful in navigating such issues to date and we remain confident about the positive future potential for our business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | "High teens" revenue growth (upgraded guidance) | FY23 |
| Biologics contract fulfilment | Fulfil long-term contract with Zoetis using newly certified facility | Undated (certifications now in place) |
| Sterile fill-finish operations | GMP-compliant production of injectables for clinical supplies | From Q4 FY23 onwards |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue from operations | ₹786 cr, +23% YoY |
| Reported revenue | ₹803 cr, +23% YoY |
| Reported EBITDA | ₹248 cr, +15% YoY |
| EBITDA margin (reported) | 30.9%, vs 33.1% in Q3 FY22 |
| EBITDA margin (from operations) | 29.4%, vs 31.7% in Q3 FY22 |
| PAT before exceptional item | ₹110 cr, +5% YoY |
| PAT margin | 13.7%, vs 15.9% in Q3 FY22 |
| 9M FY23 revenue from operations | ₹2,199 cr, +19% YoY |
| 9M FY23 PAT before exceptional item | ₹286 cr, +5% YoY |
| Full-year revenue growth guidance | high teens, upgraded, on track |
| Staff costs | ₹219 cr, 27.9% of revenue from ops, +12% YoY |
| Material costs | ₹206 cr, 26.2% of revenue from ops, +20% YoY |
| Foreign exchange fluctuation | loss of ₹16 cr, vs gain of ₹20 cr in Q3 FY22 |
| Depreciation and amortisation | ₹95 cr, +21% YoY |
| Finance costs | ₹14 cr, +46% YoY |
| Cash and cash equivalents | ₹171 cr as of 31 Dec 2022, vs ₹262 cr as of 31 Mar 2022 |
| Net borrowings (current + non-current) | ₹811 cr as of 31 Dec 2022, vs ₹790 cr as of 31 Mar 2022 |
| Headcount (scientists) | more than 5,200 |